FI955136A0 - Stabila, flytande kompositioner av gamma-interferon - Google Patents

Stabila, flytande kompositioner av gamma-interferon

Info

Publication number
FI955136A0
FI955136A0 FI955136A FI955136A FI955136A0 FI 955136 A0 FI955136 A0 FI 955136A0 FI 955136 A FI955136 A FI 955136A FI 955136 A FI955136 A FI 955136A FI 955136 A0 FI955136 A0 FI 955136A0
Authority
FI
Finland
Prior art keywords
gamma
stable
liquid compositions
gamma interferon
ifn
Prior art date
Application number
FI955136A
Other languages
English (en)
Finnish (fi)
Other versions
FI111442B (sv
FI955136A (sv
Inventor
Tue Nguyen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI955136A0 publication Critical patent/FI955136A0/sv
Publication of FI955136A publication Critical patent/FI955136A/sv
Application granted granted Critical
Publication of FI111442B publication Critical patent/FI111442B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
FI955136A 1993-05-12 1995-10-27 Förfarande för framställning av en stabil, vattenhaltig farmaceutisk sammansättning FI111442B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6032793A 1993-05-12 1993-05-12
US6032793 1993-05-12
US9404928 1994-05-04
PCT/US1994/004928 WO1994026302A1 (en) 1993-05-12 1994-05-04 Stable liquid compositions of gamma interferon

Publications (3)

Publication Number Publication Date
FI955136A0 true FI955136A0 (sv) 1995-10-27
FI955136A FI955136A (sv) 1995-10-27
FI111442B FI111442B (sv) 2003-07-31

Family

ID=22028807

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955136A FI111442B (sv) 1993-05-12 1995-10-27 Förfarande för framställning av en stabil, vattenhaltig farmaceutisk sammansättning

Country Status (23)

Country Link
EP (1) EP0697887B1 (sv)
JP (1) JP4053586B2 (sv)
KR (1) KR100330325B1 (sv)
CN (1) CN1120724C (sv)
AT (1) ATE173632T1 (sv)
AU (1) AU683469B2 (sv)
CA (1) CA2159602C (sv)
CZ (1) CZ285389B6 (sv)
DE (1) DE69414841T2 (sv)
DK (1) DK0697887T3 (sv)
ES (1) ES2126114T3 (sv)
FI (1) FI111442B (sv)
GR (1) GR3029286T3 (sv)
HK (1) HK1008303A1 (sv)
HU (1) HUT72980A (sv)
IL (1) IL109350A (sv)
NO (1) NO320069B1 (sv)
NZ (1) NZ266354A (sv)
PL (1) PL176079B1 (sv)
SK (1) SK280958B6 (sv)
TW (1) TW275585B (sv)
WO (1) WO1994026302A1 (sv)
ZA (1) ZA942955B (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
ATE255903T1 (de) * 1995-11-07 2003-12-15 Genentech Inc Stabilisierende formulierung für ngf
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
JP3493866B2 (ja) * 1995-12-27 2004-02-03 ライオン株式会社 発泡性口腔用組成物
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
EP1516627A1 (en) * 2003-09-17 2005-03-23 CONARIS research institute AG Interferon-Gamma for the treatment of diseases associated with the NOD2 gene
JP5137055B2 (ja) * 2006-03-10 2013-02-06 塩野義製薬株式会社 安定化されたインターフェロン−γ組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956B2 (en) * 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation

Also Published As

Publication number Publication date
ZA942955B (en) 1995-10-30
HK1008303A1 (en) 1999-05-07
NO954544D0 (no) 1995-11-10
TW275585B (sv) 1996-05-11
PL311639A1 (en) 1996-03-04
JPH08510242A (ja) 1996-10-29
JP4053586B2 (ja) 2008-02-27
CA2159602A1 (en) 1994-11-24
SK280958B6 (sk) 2000-10-09
KR100330325B1 (ko) 2002-11-01
KR960702320A (ko) 1996-04-27
DE69414841T2 (de) 1999-06-02
PL176079B1 (pl) 1999-04-30
FI111442B (sv) 2003-07-31
AU683469B2 (en) 1997-11-13
DK0697887T3 (da) 1999-08-09
HUT72980A (en) 1996-06-28
CZ285389B6 (cs) 1999-07-14
ES2126114T3 (es) 1999-03-16
CZ295595A3 (en) 1996-04-17
DE69414841D1 (de) 1999-01-07
CN1122575A (zh) 1996-05-15
CA2159602C (en) 2008-08-26
CN1120724C (zh) 2003-09-10
NO320069B1 (no) 2005-10-17
IL109350A0 (en) 1994-07-31
AU6782294A (en) 1994-12-12
IL109350A (en) 2001-01-28
NO954544L (no) 1995-11-10
FI955136A (sv) 1995-10-27
EP0697887B1 (en) 1998-11-25
NZ266354A (en) 1997-06-24
HU9503223D0 (en) 1996-01-29
WO1994026302A1 (en) 1994-11-24
EP0697887A1 (en) 1996-02-28
SK137895A3 (en) 1997-02-05
ATE173632T1 (de) 1998-12-15
GR3029286T3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
FI955136A0 (sv) Stabila, flytande kompositioner av gamma-interferon
TW229208B (sv)
ITRM920361A1 (it) Composizioni farmaceutiche contenenti un composto allilamminico quale principio attivo.
UA32525C2 (uk) Стійка до шлункового соку форма лікарського засобу на основі пантопразолу для орального введення
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
ES479423A1 (es) Procedimiento para la preparacion de 2-2-tenoiltio-propio- nil-glicina.
IT8124897A0 (it) Composizione farmaceutica per la terapia di calcolosi renale infetta.
DE69005241D1 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen.
WO2001018039A3 (en) INCREASED PRODUCTION OF INTERFERON-$g(a)
ITRM920551A1 (it) Composizioni farmaceutiche somministrabili per via intranasale contenenti calcitonina quale principio attivo.
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
IT8224219A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.
ITMI913306A1 (it) Composizioni farmaceutiche per la somministrazione nasale di polipeptidi.
ITMI920214A1 (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
IT8323911A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.

Legal Events

Date Code Title Description
MA Patent expired